Human Metapneumovirus, Australia, 2001–2004 by Sloots, Theo P. et al.
Human
Metapneumovirus,
Australia,
2001–2004
Theo P. Sloots,*†‡§1 Ian M. Mackay,*†‡1
Seweryn Bialasiewicz,*† Kevin C. Jacob,*†‡
Emily McQueen,*† Gerald B. Harnett,¶ 
David J. Siebert,§ I. Brent Masters,* 
Paul R. Young,‡ and Michael D. Nissen*†‡§
We examined 10,025 respiratory samples collected for
4 years (2001–2004) and found a 7.1% average annual
incidence of human metapneumovirus. The epidemic peak
of infection was late winter to spring, and genotyping
showed a change in predominant viral genotype in 3 of the
4 years.
H
uman metapneumovirus (HMPV) is now recognized
as a substantial cause of acute respiratory infection,
particularly in children; it has phenotypic and clinical char-
acteristics that are similar to those of respiratory syncytial
virus (RSV) (1,2). HMPV is ubiquitous; it infects most
children at an early age, and distinct epidemic peaks are
reported in the winter months (1,3–6). However, many of
theses studies were conducted in the Northern Hemisphere
and involved samples collected during a relatively short
period; few data exist from extended studies over several
years that involve populations in other parts of the world.
Although 2 main HMPV types are recognized (A and
B) (1,3,7), each with 2 subtypes (A1, A2; B1, B2) (8), the
extent of genetic variation of circulating HMPV subtypes
over time has not been extensively examined. We sought to
determine the incidence and seasonal distribution of
HMPV in an Australian population from 2001 to 2004 and
to establish the pattern of genotype distribution during
those 4 years by examining the genetic variability of the P
gene in 640 of 707 HMPV-positive samples.
The Study
The necessary ethics approval for this study was
obtained from the Royal Children’s Hospital ethics com-
mittee. We collected nasopharyngeal aspirate (NPA) spec-
imens from January 2001 through December 2004 from
patients with acute lower respiratory tract infection in
Queensland, Australia. Patients were from 3 months to 93
years of age (mean 8.2 years, median 1.37 years), and
78.1% of specimens were from children <5 years of age.
Nucleic acids were extracted from 0.2 mL of each NPA
specimen by using the High Pure Viral Nucleic Acid kit
(Roche Diagnostics, Mannheim, Germany), according to
the manufacturer’s instructions. Extracts were analyzed for
HMPV sequences by reverse transcriptase PCR (9). For
samples collected during 2001 and 2002, other viral respi-
ratory pathogens were detected by using a direct fluores-
cent antibody assay (DFA) in combination with a
culture-augmented DFAmethod (10). For samples collect-
ed in 2003 and 2004, these pathogens were detected by
multiplex PCR (10).
Of 10,025 NPAspecimens tested, 707 were positive for
HMPV, for an overall incidence of 7.1% during the 4
years. The youngest HMPV-positive patient was 4 months
old, and the oldest was 79 years. In children (<18 years of
age) the incidence of virus was 7.4%, and 91.9% of
HMPV-positive children were <5 years of age. The season-
al distribution of HMPV infection showed a distinctive
pattern for each of the 4 years studied (Figure 1). In 2001,
HMPV showed broad seasonal activity; incidence was
>5% in 3 consecutive seasons (autumn, winter, and spring)
and peaked at 10.6% in the spring (September–
November). In 2002 and 2004, most HMPVactivity was in
spring, (incidence of 13.6% and 15.4%, respectively), with
little evidence during autumn (March–May). In 2003, the
peak incidence of 9.0% occurred in winter (June–August)
and persisted into spring (5.4%). In all years, virus was
present well into summer (December–February), with an
incidence ranging from 2.5% to 5.2%. On examination of
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Figure 1. Seasonal incidence of human metapneumovirus,
Queensland, Australia, 2001–2004. Su, summer (December–
February); Au, autumn (March–May); W, winter (June–August);
Sp, spring (September–November).those samples collected in 2003 and 2004, which were all
previously analyzed for common respiratory viruses by
PCR, HMPV was the most frequently detected respiratory
virus in children during the spring of each year. Expressed
as an annual average over the 4 years studied, the predom-
inant viral pathogen was RSV (9.2%), followed by HMPV
(7.1%), influenza A (3.5%), parainfluenza virus 3 (2.3%),
and adenovirus (1.3%). In 6.8% of HMPV-positive cases,
evidence of co-infection with another respiratory virus was
seen; 20 patients were concurrently infected with an aden-
ovirus, 10 with influenza A virus, 8 with RSV, 9 with
parainfluenza virus 3, and 1 with parainfluenza virus 2.
Amplification products generated directly from 640
HMPV-positive NPA specimens were genotyped as previ-
ously described (11) (GenBank accession nos.
DQ112292–DQ112320 and DQ121378–DQ121384). Data
showed that all 4 viral subtypes cocirculated during each
of the 4 years studied (Table 1, Figure 2). However, a dif-
ferent subtype predominated during 3 of the 4 years:
HMPV subtype A1 was dominant in 2001, subtype A2 in
2002 and 2003, and subtype B1 in 2004 (Table 1).
Clinical records from 273 patients who were positive
for HMPV were scrutinized, and data describing clinical
features and length of hospital stay were recorded. Of
these patients, 203 (74.4%) were admitted to hospital with
a median length of admission of 3 days and a mean of 6.5
days. The predominant clinical features were cough (63%),
rhinorrhea (61%), respiratory crackles/crepitations (60%),
and fever (57%) (Table 2). Ninety (33.9%) of the 273
patients had a chest radiograph, and 77 (85.6%) patients
showed bilateral parahilar peribronchial infiltrates consis-
tent with a lower respiratory tract infection. Disease sever-
ity of the 273 HMPV-positive patients was classified as
mild (46.8%), moderate (42.5%), and severe (10.7%),
based on the use of supplemental oxygen and fluids and
length of hospital stay.
Conclusions
This study of HMPV infection is the largest so far
reported. The results of recent, similar studies suggested
that peak periods of infection with HMPV predominate
during winter in the Northern Hemisphere. However, this
finding has not been extensively examined over an extend-
ed period with a large, continuous sample. Our study found
that the peak period of HMPV infection in Queensland,
Australia, occurs predominantly in spring (August–
October) but that HMPV can be detected in every month.
This finding suggests that HMPV activity, like RSV activ-
ity, occurs in the community throughout the year, and
peaks of infection are a result of seasonal environmental
factors.
Although RSV predominated in all years, HMPV was
the second most frequently detected virus in each year
studied. The low rate of co-infection of HMPV with other
respiratory viruses (including RSV) suggests that co-infec-
tion may not be common in our community. When analyz-
ing disease severity in this sample with a 2-sided test of
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Figure 2. Phylogenetic analysis of the 182-nucleotide fragment  of
the phosphoprotein gene fragment of human metapneumovirus
detected in respiratory samples collected in Australia. Sequences
of avian pneumovirus (APV) type C (GenBank accession nos.
AF176590 and AF176591) were used as outgroups to root the
tree. Nucleotide sequences were aligned by using BioEdit version
7.0.0 and were subjected to neighbor-joining analysis with MEGA
version 3.0 with 500 random bootstraps. CAN and NC, Canada;
JPS, Japan; NL00–1, the Netherlands; Q, Queensland, Australia.proportions, we saw no significant difference between
patients with a co-infection and those without. Therefore,
our data did not support the suggestion by others that co-
infection of HMPV with RSV or other viral respiratory
pathogens is a risk factor for severe disease (6).
The shift in predominant HMPV genotype observed in
this study was similar to those reported for RSV and
influenza viruses (6) and can be attributed to changes in
immunity of the population in response to antigenic differ-
ences between the predominant circulating strains (12,13).
However, a relationship between genotype and disease
severity, as previously established for RSV (14,15), did not
appear to apply for HMPV, but we plan to examine this
relationship further.
The clinical features associated with HMPV infection
in this study were not sufficiently distinctive to clinically
differentiate it from other respiratory viral infections in
children, particularly those attributed to RSV. In addition,
few patients (10.6%) had severe disease, but most (76%)
were sufficiently ill to be admitted and treated in the hos-
pital for >3 days, which represents a substantial amount in
healthcare costs.
Finally, this comprehensive study, conducted for 48
months, is the first one aimed at establishing an accurate
estimate of the incidence and seasonal distribution of
HMPV infection and to determine the genetic variation of
HMPVcirculating in our population. The clinical spectrum
of infection in a substantial proportion of HMPV-positive
patients has been described, and studies are continuing to
fully elucidate the clinical effect of infection with this
virus in our community.
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